Diagnostic Yield of Initial and Consecutive Blood Cultures in Children With Cancer and Febrile Neutropenia.


Journal

Journal of the Pediatric Infectious Diseases Society
ISSN: 2048-7207
Titre abrégé: J Pediatric Infect Dis Soc
Pays: England
ID NLM: 101586049

Informations de publication

Date de publication:
26 Mar 2021
Historique:
received: 26 11 2019
accepted: 30 03 2020
pubmed: 9 4 2020
medline: 19 8 2021
entrez: 9 4 2020
Statut: ppublish

Résumé

The timing and necessity of repeated blood cultures (BCs) in children with cancer and febrile neutropenia (FN) are unknown. We evaluated the diagnostic yield of BCs collected pre- and post-empiric FN antibiotics. Data collected prospectively from the Australian Predicting Infectious ComplicatioNs in Children with Cancer (PICNICC) study were used. Diagnostic yield was calculated as the number of FN episodes with a true bloodstream infection (BSI) detected divided by the number of FN episodes that had a BC taken. A BSI was identified in 13% of 858 FN episodes. The diagnostic yield of pre-antibiotic BCs was higher than of post-antibiotic cultures (12.3% vs 4.4%, P < .001). Two-thirds of the post-antibiotic BSIs were associated with a new episode of fever or clinical instability, and only 2 new BSIs were identified after 48 hours of empiric antibiotics and persistent fever. A contaminated BC was identified more frequently in post-antibiotic cultures. In the absence of new fever or clinical instability, BCs beyond 48 hours of persistent fever have limited yield. Opportunity exists to optimize BC collection in this population and reduce the burden of unnecessary tests on patients, healthcare workers, and hospitals.

Sections du résumé

BACKGROUND BACKGROUND
The timing and necessity of repeated blood cultures (BCs) in children with cancer and febrile neutropenia (FN) are unknown. We evaluated the diagnostic yield of BCs collected pre- and post-empiric FN antibiotics.
METHODS METHODS
Data collected prospectively from the Australian Predicting Infectious ComplicatioNs in Children with Cancer (PICNICC) study were used. Diagnostic yield was calculated as the number of FN episodes with a true bloodstream infection (BSI) detected divided by the number of FN episodes that had a BC taken.
RESULTS RESULTS
A BSI was identified in 13% of 858 FN episodes. The diagnostic yield of pre-antibiotic BCs was higher than of post-antibiotic cultures (12.3% vs 4.4%, P < .001). Two-thirds of the post-antibiotic BSIs were associated with a new episode of fever or clinical instability, and only 2 new BSIs were identified after 48 hours of empiric antibiotics and persistent fever. A contaminated BC was identified more frequently in post-antibiotic cultures.
CONCLUSIONS CONCLUSIONS
In the absence of new fever or clinical instability, BCs beyond 48 hours of persistent fever have limited yield. Opportunity exists to optimize BC collection in this population and reduce the burden of unnecessary tests on patients, healthcare workers, and hospitals.

Identifiants

pubmed: 32267508
pii: 5817770
doi: 10.1093/jpids/piaa029
doi:

Substances chimiques

Anti-Bacterial Agents 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

125-130

Subventions

Organisme : Medical Research Council
ID : G0800472
Pays : United Kingdom
Organisme : Department of Health
ID : PDF-2014-07-072
Pays : United Kingdom

Informations de copyright

© The Author(s) 2020. Published by Oxford University Press on behalf of The Journal of the Pediatric Infectious Diseases Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Auteurs

Gabrielle M Haeusler (GM)

Department of Infectious Diseases, Peter MacCallum Cancer Centre, Melbourne, Australia.
National Health and Medical Research Council, National Centre for Infections in Cancer, Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia.
Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia.
Paediatric Integrated Cancer Service, Victoria State Government, Melbourne, Australia.
Infection Diseases Unit, Department of General Medicine, Royal Children's Hospital, Melbourne, Australia.
Murdoch Children's Research Institute, Melbourne, Australia.

Richard De Abreu Lourenco (R)

Centre for Health Economics Research and Evaluation, University of Technology, Sydney, Australia.

Hannah Clark (H)

Paediatric Integrated Cancer Service, Victoria State Government, Melbourne, Australia.

Karin A Thursky (KA)

Department of Infectious Diseases, Peter MacCallum Cancer Centre, Melbourne, Australia.
National Health and Medical Research Council, National Centre for Infections in Cancer, Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia.
Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia.
Department of Medicine, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, Australia.
NHMRC, National Centre for Antimicrobial Stewardship, Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.
Victorian Infectious Diseases Service, Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.

Monica A Slavin (MA)

Department of Infectious Diseases, Peter MacCallum Cancer Centre, Melbourne, Australia.
National Health and Medical Research Council, National Centre for Infections in Cancer, Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia.
Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia.
Department of Medicine, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, Australia.
Victorian Infectious Diseases Service, Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.

Franz E Babl (FE)

Murdoch Children's Research Institute, Melbourne, Australia.
Department of Emergency Medicine, Royal Children's Hospital, Melbourne, Australia.
Department of Paediatrics, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Australia.

Francoise Mechinaud (F)

Unité d'hématologie immunologie pédiatrique, Hopital Robert Debré, APHP Nord Université de Paris, Paris, France.

Frank Alvaro (F)

Children's Cancer Department, John Hunter Children's Hospital, University of Newcastle, Newcastle, Australia.

Julia Clark (J)

Infection Management Service, Queensland Children's Hospital, Children's Health Queensland Hospital and Health Service, Brisbane, Australia.

Bhavna Padhye (B)

Kid's Cancer Centre, Westmead Children's Hospital, Sydney, Australia.

Marianne Phillips (M)

Department of Oncology, Perth Children's Hospital, Perth, Australia.

Leanne Super (L)

Children's Cancer Centre, Monash Children's Hospital, Monash Health, Melbourne, Australia.

Heather Tapp (H)

Department of Oncology, Women's and Children's Hospital, Adelaide, Australia.

Thomas Walwyn (T)

Department of Oncology, Perth Children's Hospital, Perth, Australia.

David Ziegler (D)

Kid's Cancer Centre, Sydney Children's Hospital, Sydney, Australia.

Robert Phillips (R)

Centre for Reviews and Dissemination, University of York, York, United Kingdom.

Leon J Worth (LJ)

Department of Infectious Diseases, Peter MacCallum Cancer Centre, Melbourne, Australia.
National Health and Medical Research Council, National Centre for Infections in Cancer, Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia.
Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH